STOCK TITAN
  1. Home
  2. News
  3. AZN

AstraZeneca PLC - AZN STOCK NEWS

Welcome to our dedicated page for AstraZeneca PLC news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca PLC stock.

AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.

The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.

Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.

Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.

With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.

News

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Rhea-AI Summary
Positive results from the TROPION-Breast01 phase 3 trial showed that datopotamab deruxtecan (Dato-DXd) reduced the risk of disease progression or death by 37% in patients with advanced breast cancer. Median progression-free survival was 2 months longer with Dato-DXd compared to chemotherapy. The drug also demonstrated a confirmed objective response rate of 36.4% compared to 22.9% with chemotherapy. The trial is ongoing to assess overall survival.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
clinical trial
-
News

ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Rhea-AI Summary
ENHERTU receives approval in the EU for the treatment of advanced non-small cell lung cancer with HER2 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
none
-
News

Datopotamab deruxtecan plus IMFINZI® (durvalumab) demonstrated robust and durable tumor responses in 1st-line treatment of patients with metastatic triple-negative breast cancer in BEGONIA Phase Ib/II trial

Rhea-AI Summary
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan plus IMFINZI shows a confirmed objective response rate of 79% in patients with triple-negative breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Rhea-AI Summary
Updated results from the BEGONIA phase 1b/2 trial showed that the combination of datopotamab deruxtecan and durvalumab demonstrated a confirmed objective response rate of 79% in patients with previously untreated advanced or metastatic triple negative breast cancer. The median progression-free survival was 13.8 months and the median duration of response was 15.5 months. The safety profile of the combination was consistent with known profiles of both agents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

Rhea-AI Summary
Positive results from the DUO-E Phase III trial show that IMFINZI plus chemotherapy, followed by either IMFINZI monotherapy or IMFINZI plus LYNPARZA, improves progression-free survival in patients with advanced or recurrent endometrial cancer. The combination treatments reduced the risk of disease progression or death by 45% and 29% compared to chemotherapy alone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

TAGRISSO® (osimertinib) plus chemotherapy reduced the risk of disease progression in the brain by 42% in patients with EGFR-mutated advanced lung cancer and brain metastases at baseline

Rhea-AI Summary
AstraZeneca's TAGRISSO shows improvement in CNS progression-free survival in FLAURA2 Phase III trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

IMFINZI® (durvalumab) plus chemotherapy more than doubled pathologic complete response rate in resectable early-stage gastric and gastroesophageal junction cancers versus chemotherapy alone

Rhea-AI Summary
Positive results from the MATTERHORN Phase III trial showed that AstraZeneca's IMFINZI in combination with standard-of-care chemotherapy demonstrated a significant improvement in pathologic complete response for patients with gastric and gastroesophageal junction cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.92%
Tags
none
-
News

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

Rhea-AI Summary
Meharry Medical College and partners launch Together for CHANGE initiative to increase genomic data for people of African ancestry and enhance representation in STEM careers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none
-
News

SOPHiA GENETICS Enters New Collaboration with Memorial Sloan Kettering Cancer Center and AstraZeneca to Address Global Inequalities in Comprehensive Cancer Care

Rhea-AI Summary
SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center, and AstraZeneca collaborate to improve global access to cancer testing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
none
News

TAGRISSO® Plus Chemotherapy Granted Priority Review in the US for Patients with EGFR-Mutated Advanced Lung Cancer

Rhea-AI Summary
AstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO® (osimertinib) in combination with chemotherapy has been accepted and granted Priority Review in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The FDA action date for their regulatory decision is anticipated during the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
none

FAQ

What is the current stock price of AstraZeneca PLC (AZN)?

The current stock price of AstraZeneca PLC (AZN) is $67.01 as of January 10, 2025.

What is the market cap of AstraZeneca PLC (AZN)?

The market cap of AstraZeneca PLC (AZN) is approximately 207.8B.

What is AstraZeneca PLC?

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It is headquartered in Cambridge, England.

What therapeutic areas does AstraZeneca focus on?

AstraZeneca’s product portfolio includes drugs across several therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Where does AstraZeneca generate most of its revenue?

A significant portion of AstraZeneca’s revenue comes from international markets, with the United States accounting for nearly one-third of its sales.

What is the recent collaboration between AstraZeneca and Nona Biosciences about?

AstraZeneca and Nona Biosciences have entered into a global license agreement to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology.

What is C-CAR031?

C-CAR031 is a GPC3-targeted CAR-T therapy developed by AstraZeneca and AbelZeta Pharma for treating hepatocellular carcinoma (HCC). Initial clinical results have shown promising safety and efficacy data.

What is rilvegostomig?

Rilvegostomig is a PD-1/TIGIT bispecific antibody developed by AstraZeneca in collaboration with Compugen Ltd. It is currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer.

What are some of AstraZeneca’s key recent achievements?

Recent achievements include a global license agreement with Nona Biosciences for oncology therapies, collaboration with AbelZeta Pharma on C-CAR031, and partnership with Compugen Ltd. for developing rilvegostomig.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered at the Cambridge Biomedical Campus in Cambridge, England.

When was AstraZeneca formed?

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK.

What is the focus of AstraZeneca’s research and development?

AstraZeneca focuses on research and development in pharmaceuticals and biotechnology, particularly in creating treatments for various major therapeutic areas including cancer, respiratory diseases, cardiovascular conditions, and more.
Stock AZN logo
AstraZeneca PLC

Nasdaq:AZN

AZN Rankings

#40 Ranked by Market Cap
#1616 Ranked by Dividends

AZN Stock Data

207.80B
3.10B
0.01%
16.77%
0.32%
Drug Manufacturers - General
Healthcare
Link
United States of America
Cambridge